Yifei Sanjie pill combined with gefitinib reduces the progression of EGFR-TKIs-resistant non-small cell lung cancer via YAP/ANKRD1 axis - PubMed
4 hours ago
- #NSCLC
- #YAP/ANKRD1 axis
- #EGFR-TKIs resistance
- Yifei Sanjie pill (YFSJ) combined with gefitinib reduces progression of EGFR-TKIs-resistant non-small cell lung cancer (NSCLC).
- The study explores mechanisms via YAP/ANKRD1 axis using in vitro, in vivo, and systems biology approaches.
- UPLC-MS/MS identified 1624 compounds in YFSJ, with 1177 confidently identified.
- Combination therapy showed synergistic effects, lowering IC50 values compared to individual drugs.
- YFSJ and gefitinib together suppressed clonogenic ability and migration in H1975 cells.
- In vivo, the combination markedly suppressed proliferation in H1975-derived xenografts.
- ANKRD1 identified as a potential biomarker for EGFR exon 20 mutation-driven resistance.
- Therapy blocks YAP/ANKRD1 axis, reducing resistance and promoting apoptosis.
- YFSJ with gefitinib represents a novel therapeutic strategy for EGFR exon 20 mutation-resistant NSCLC.